Proteases in gastrointestinal neoplastic diseases

Clinica Chimica Acta

Volumn 291, Issue 2, 2000, Pages 171-187

  Herszényi, László ^b   Plebani, Mario ^a   Carraro, Paolo ^a   De Paoli, Massimo ^a   Roveroni, Giovanni ^a   Cardin, Romilda ^a   Foschia, Francesca ^a   Tulassay, Zsolt ^b   Naccarato, Remo ^a   Farinati, Fabio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Cancer; Cathepsin; Gastrointestinal tract; Plasminogen activator; Prognosis; Protease

Indexed keywords

CATHEPSIN B; CYSTEINE PROTEINASE; PROTEINASE; SERINE PROTEINASE;

CANCER GROWTH; CANCER INVASION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; METASTASIS; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE LEVEL;

EID: 0034651811     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00227-2     Document Type: Article

References (88)

1. Liotta L.A., Rao C.N., Barsky S.H. Tumor invasion and the extracellular matrix. Lab Invest. 49:1983;636-649.
2. Hart I.R., Saini A. Biology of tumour metastasis. Lancet. 339:1992;1453-1457.
3. Nigam A.K., Pignatelli M., Boulos P.B. Current concepts in metastasis. Gut. 35:1994;996-1000.
4. Moscatelli D., Rifkin D. Membrane and matrix localisation of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta. 948:1988;67-85.
5. Yurchenko P.D., Schittny J.C. Molecular architecture of basement membranes. FABES J. 4:1990;1577-1590.
6. Pauli B.U., Knudson W. Tumor invasion: a consequence of destructive and compositional matrix alterations. Hum Pathol. 19:1988;628-639.
7. Aznavoorian S., Stracke M.L., Krutzsch H., Schiffmann E., Liotta L.A. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol. 110:1990;1427-1438.
8. Sloane B.F., Moin K., Krepela E., Rozhin J. Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev. 9:1990;333-352.
9. Brown P.D., Levy A.T., Margulies I., Liotta L.A., Stetler-Stevenson W.G. Independent expression and cellular processing of the 72-kDa type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50:1990;6184-6191.
10. Guirguis R., Margulies I., Tarabelotti G., Schiffman E., Liotta L. Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature. 329:1987;261-263.
11. Emonard H., Grimaud J.A. Matrix metalloproteins: A review. Cell Mol Biol. 36:1990;131-153.
12. Polgar L. Common feature of the four types of protease mechanisms. Biol Chem Hoppe-Seyler. 371:(Suppl):1990;327-331.
13. Yokota S., Tsuji H., Kato K. Immunocytochemical localisation of cathepsin B in rat kidney: Light microscopic study using indirect immunoenzyme technique. J Histochem Biochem. 4:1986;891-897.
14. Kobayashi H., Schmitt M., Goretzki L., Chuchowolski N., Calvete J., Kramer M. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem. 266:1991;5147-5152.
15. Howie A.J., Burnett D. The distribution of cathepsin B in human tissues. J Pathol. 145:1985;307-314.
16. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 44:1985;139-266.
17. Vassali J.D., Sappino A.P., Belin D. The plasminogen activator/plasmin system. J Clin Invest. 88:1991;1067-1072.
18. Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis. 2:1988;246-250.
19. Cohen R., Xi X.P., Crowley C., Lucas B., Levinson B., Shuman M. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood. 78:1991;479-487.
20. Ellis V., Pyke C., Eriksen J., Solberg H., Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad. 667:1992;13-31.
21. Hollas W., Blasi F., Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 51:1991;3690-3695.
22. Reiter L., Kruithof E., Cajot J., Sordat B. The role of urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int J Cancer. 53:1993;444-450.
23. Taniguchi T., Lemoine N.R., Kakkar A.K. Urokinase receptor is a key player in tumour progression. Gut. 43:1998;739-740.
24. Milburn J.J. Role of urokinase, its receptor and serpins in colorectal carcinoma. Gastroenterology. 107:1994;1555-1559.
25. Sprengers E.D., Kluft C. Plasminogen activator inhibitors. Blood. 69:1987;381-387.
26. Shi G.Y., Wang S.J., Chang B.I., Tasi C.F., Lin M.T., Chang W.C., Jen C.J., Wu W.L. Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells. Thromb Res. 81:1996;75-84.
27. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:1991;327-336.
28. Murphy G., Atkinson S., Ward R., Gavrilovic J., Reynolds J.J. The role or plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad. 667:1992;1-12.
29. Schmidt M., Heinrich J., Pfeifer M. Proteolytic activities in bronchoalveolar lavage fluid in pneumonia and chronic bronchitis. Pneumonologie. 44:1990;308-309.
30. Baricos W.H., Shah S.V. Proteolytic enzymes as mediators of glomerular injury. Kidney Int. 40:1991;161-173.
31. Gabrijelcic D., Annan-Prah A., Rodic B., Rozman B., Cotic V., Turk V. Determination of cathepsin B in sera and sinovial fluids of patients with different joint diseases. J Clin Chem Clin Biochem. 28:1990;149-153.
32. Yamamoto H., Murawaki Y., Kawasaki H. Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver. Res Commun Chem Pathol Pharm. 76:1992;95-112.
33. Korsten M.A., Dlugoz J.W. Role of cathepsin B in the pathogenesis of acute pancreatitis. Int J Pancreatol. 14:1993;149-155.
34. Weiss S.J. Tissue destruction by neutrophils. N Engl J Med. 320:1989;365-376.
35. Herszényi L., Plebani M., Carraro P., De Paoli M., Cardin R., Di Mario F., Kusstatscher S., Naccarato R., Farinati F. Imapaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol. 92:1997;843-847.
36. Duffy M.J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 10:1992;145-155.
37. Sloane B.F. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1:1990;137-152.
38. Murnane M.J., Sheahan K., Ozdemirli M., Shuja S. Stage specific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res. 51:1991;1137-1142.
39. Corticchiatto O., Cajot J.F., Abrahamson M., Chan S.J., Keppler D., Sordat B. Cystatin C and cathepsin B in human colonic carcinoma: expression by cell lines and matrix degradation. Int J Cancer. 52:1992;645-652.
40. Thomsen C., Schmitt M., Goretzki L., Oppelt P., Pache L., Detmar P., Janicke F., Graeff H. Prognostic value of cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res. 1:1995;741-746.
41. Ohta T., Terada T., Nagakawa T., Tajima H., Itoh H., Fonseca L. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer. 69:1994;152-156.
42. Blasi F. Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol Suppl. 3:1993;21-23.
43. Noguchi-Takino M., Endo Y., Yonemura Y., Sasaki T. Relationship between expression of plasminogen activator system and metastatic ability in human cancers. Int J Oncol. 8:1996;97-105.
44. Gorelik E. Protective effect of fibrin on tumour metastasis. Fibrinolysis. 6:(Suppl 1):1991;35-38.
45. Fidler I.J. Cancer metastasis. Br Med Bull. 47:1991;157-177.
46. Koshikawa N., Yasumitsu H., Umeda M., Miyazaki K. Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res. 52:1992;5046-5053.
47. Fazioli F., Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for antimetastatic therapy? Trends Pharmacol Sci. 15:1994;25-29.
48. Cajot J., Bamat J., Bergonzelli G.E., Kruithof E.K.O., Medcalf R.L., Testuz J. Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA. 87:1990;6939-6943.
49. Kwaan H.C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 11:1992;291-311.
50. Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J.J., Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50:1990;6827-6829.
51. Grondahl-Hansen J., Christensen I.J., Rosenquist C., Brünner N., Mouridsen H.T., Dano K. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:1993;2513-2521.
52. Bouchet C., Spyratos F., Martin P.M., Hacéne K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator (UPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 69:1994;398-405.
53. Pedersen H., Brunner N., Francis D., Osterlind K., Ronne E., Hansen H.H., Dano K., Grondahl-Hansen J. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large lung cancer tissue. Cancer Res. 54:1994;4671-4675.
54. Kirchheimer J.C., Köller A., Binder B.R. Isolation and characterisation of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta. 797:1984;256-265.
55. Landau B.J., Kwaan H.C., Verrusio E.N., Brem S.S. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 in malignant human brain tumors. Cancer Res. 54:1994;1105-1108.
56. Sappino A.P., Belin D., Huarte S., Hirschel-Scholz S., Saurat J.H., Vasalli J.D. Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest. 88:1991;1074-1080.
57. Kristensen P., Pyke C., Lund L.R., Andreasen P.A., Dano K. Plasminogen activator inhibitor type-1 in Lewis lung carcinoma. Histochemistry. 93:1990;559-566.
58. Cubellis M.V., Wun T.C., Blasi F. Receptor mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 9:1990;1079-1085.
59. Vasishta A., Baker P.R., Hopwood D., Holley P.M., Cuschieri A. Proteinase-like peptidase activities in malignant and non-malignant gastric tissue. Brit J Surg. 72:1985;386-388.
60. Watanabe M., Higashi T., Watanabe A., Osawa T., Sato Y., Kimura Y., Morimoto S., Shiota T., Hashimoto M., Kobayashi M., Tomoda J., Tsuji T. Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings. Biochem Med Metab Biol. 42:1989;21-29.
61. Sung M.C., Kawai K. Protease activities in gastric cancer tissues. Clin Chim Acta. 189:1990;205-210.
62. Takai S., Yamamura M., Tanaka K., Kawanashi H., Tsuji M., Nakane Y. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer. 48:1991;20-27.
63. Sier C.F.M., Verspaget H.W., Griffioen G., Ganesh S., Vloedgraven H.J.M., Lambers C.B.H.W. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut. 34:1993;80-85.
64. Nekarda H., Schmitt M., Ulm K., Wenninger A., Vogelsang H., Becker K. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 54:1994;2900-2907.
65. Plebani M., Herszényi L., Cardin R., Roveroni G., Carraro P., De Paoli M., Rugge M., Grigioni W.F., Nitti D., Naccarato R., Farinati F. Cysteine and serine proteases in gastric cancer. Cancer. 76:1995;367-375.
66. Plebani M., Herszényi L., Carraro P., De Paoli M., Roveroni G., Cardin R., Tulassay Z., Naccarato R., Farinati F. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis. 15:1997;418-425.
67. Shuja S., Sheahan K., Murnane M.J. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer. 49:1991;341-346.
68. De Bruin P.A.F., Griffioen G., Verspaget H.W., Verheijen J.H., Lamers C.B.H.W. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res. 47:1987;4654-4657.
69. Suzuki S., Hayashi Y., Wang Y., Nakamura T., Morita Y., Kawasaki K., Ohta K., Aoyama N., Kim S.R., Itoh H., Kuroda Y., Doe W.F. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut. 43:1998;798-805.
70. Farinati F., Plebani M., Di Mario F., Valiante F., Della Libera G., Fanton M.C., Naccarato R. Aspartic proteinases and gastrin in the diagnosis of gastric cancer and gastric precancerous changes. Eur J Gastroenterol Hepatol. 5:1993;707-712.
71. Farinati F., Herszényi L., Plebani M., Carraro P., De Paoli M., Cardin R., Roveroni G., Rugge M., Nitti D., Grigion W.F., D'Errico A., Naccarato R. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. Carcinogenesis. 17:1996;2581-2587.
72. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: first American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res. 52:1992;6735-6740.
73. Sheahan K.S., Shuja S., Murnane M.J. Cysteine protease activities and tumor development in human colorectal carcinoma. Cancer Res. 49:1989;3809-3814.
74. Shuja S., Sheahan K., Murnane M.J. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer. 49:1991;341-346.
75. Sier C.F.M., Vloedgraven H.J.M., Ganesh S., Griffioen G., Quax P.H., Verheijen J.H. Inactive urokinase and increased levels of its inhibitors type 1 in colorectal cancer liver metastasis. Gastroenterology. 107:1994;1449-1456.
76. Ganesh S., Sier C.F.M., Griffioen G., Vloedgraven H.J.M., de Boer A., Welvaart K., van de Velde C.J.H., van Krieken J.H.J.M., Verheijen J.H., Lamers C.B.H.W., Verspaget H.W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 54:1994;4065-4071.
77. Ganesh S., Sier C.F.M., Heerding M.M., van Krieken J.H., Griffioen G., Welvaart K., van de Velde C.J.H., van Krieken J.H.J.M., Verheijen J.H., Lamers C.B.H.W., Verspaget H.W. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer. 75:1997;1793-1801.
78. Mulcahy H.E., Duffy M.J., Gibbons D., McCarthy P., Parfrey N.A., O'Donoghue D.P. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 344:1994;583-584.
79. Campo E., Munoz J., Miquel R., Palacin A., Cardesa A., Sloane B.F., Emmert-Buck M.R. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 145:1994;301-309.
80. Buo L., Lyberg T., Jorgensen L., Johansen H.T., Aasen A.O. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMIS. 101:1993;235-241.
81. Grondahl-Hansen J., Ralfkiaer E., Kirkeby L.T., Kristensen P., Lund L.R., Dano K. Localisation of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol. 138:1991;111-117.
82. Nielsen H.J., Pappot H., Christensen I.J., Brünner N., Thorlacius-Ussing O., Moesgaard F., Dano K., Grondahl-Hansen J. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J. 316:1998;829-830.
83. Herszényi L., Plebani M., Carraro P., De Paoli M., Roveroni G., Cardin R., Tulassay Z., Naccarato R., Farinati F. Cysteine and serine proteases in colorectal cancer. Gastroenterology. 114:1998;A 610.
84. Herszényi L., Farinati F., Plebani M., Carraro P., De Paoli M., István G., Sápi Z., Naccarato R., Tulassay Z. The role of urokinase-type plasminogen activator receptor in colorectal cancer. Digestive Disease Week and the Annual Meeting of American Gastroenterological Association (AGA), 16-19 May, 1999, Orlando, USA. A-791: Abstract 4359.
85. Hirano T., Manabe T., Takeuchi S. Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote metastasis. Cancer Lett. 70:1993;41-44.
86. Huber K., Kirchheimer J.C., Ermler D., Bell C., Binder B.R. Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with α-fetoprotein. Cancer Res. 52:1992;1717-1720.
87. Huber K., Kirchheimer J.C., Sedlmayer A., Bell C., Ermler D., Binder B.R. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res. 53:1993;1788-1793.
88. Farinati F, Foschia F, Cardin R, Plebani M, De Paoli M, Gianni S, Rinaldi M, Naccarato R. Urokinase type plasminogen activator (UPA) and cathepsin B (CATB) plasma levels in gastrointestinal tract cancer. Digestive Disease Week and the Annual Meeting of American Gastroenterological Association (AGA), 16-19 May, 1999, Orlando, USA. A-635: Abstract 3495.